Emergent
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Maryland, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
400 Professional Dr Ste 400, Gaithersbur...Phone Number
(240) 631-3200Website
www.emergentbiosolutions.comRevenue
$770.2 MillionStock Symbol
EBSIndustry
ZI Rank: 15
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
14
21
24
18
21
15
About Emergent
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; RRead more
Emergent Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Emergent your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Emergent had a recent Job posting/layoffs
Emergent, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Emergent launches new products
Check if Emergent has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Emergent recently announced quarterly report
Funding: Get notified immidiatlly once Emergent has new funding data
Congratulate Masked Content for being promoted to Masked Content at Emergent
Check out if Emergent is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Emergent
Compare insights from companies similar to Emergent, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Emergent is experiencing low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Emergent is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Emergent.
Emergent financials insights
Gather financial insights about Emergent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Stock Offering
$62.5M
Emergent Tech Stack
A closer look at the technologies used by Emergent
Most Recent Scoops
Pain Point
Emergent is facing increased competitive pressure in the naloxone market following the entry of two new nasal naloxone competitors, including a new 4-milligram over-the-counter product approved on June 16, 2026, and a 10-milligram prescription agent set to launch in August 2026, accompanied by more aggressive pricing across the naloxone segment.
Pain Point, Pricing
Earnings
reported Medical Countermeasure (MCM) revenue of $168 million in Q2 2026, the highest second quarter MCM revenue since 2020, driven by multiple U.S. government contract awards and international product orders, including a $52.7 million contract modification for ACAM 2000 and a $64.5 million contract modification for botulism anti-toxin, with over 10 contract awards secured year-to-date.
Earnings, Contracts, Finance
Pain Point
recorded a non-cash impairment charge of approximately $191 million in Q2, reflecting an updated assessment of expected future cash flows in the context of current market dynamics, including pricing and competitive pressures, with the company noting the charge does not affect its cash position, liquidity, operating cash flow, or adjusted EBITDA.
Accounting, Financial Reporting, Finance, Risk
Open Position
Hiring Plans
Hiring Plans
Emergent News & Media
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company’s investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth.INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of face value. Following completion of theEmergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significan
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Emergent
Sign Up For FreeTo access detailed company insights
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Viv... Read More
